)
XVIVO Perfusion (XVIVO) investor relations material
XVIVO Perfusion Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 2025 net sales were SEK 189 million, down 5% year-over-year, but organic growth excluding Heart trial revenue was 6% in local currencies, with EBITDA margin recovering to 19% as destocking effects subsided.
Abdominal segment showed strong growth, while Thoracic sales declined due to lower Heart trial revenue, currency effects, and softer Lung market.
Strategic investments and partnerships in U.S. services and commercial footprint were made to support future Heart business and address resource constraints.
Regulatory and clinical projects are progressing, but timelines for Heart approval in the EU remain uncertain.
Operating cash flow was positive in Q3 despite ongoing inventory buildup.
Financial highlights
Q3 net sales: SEK 189 million, with organic growth of 6% excluding Heart trial revenue; year-to-date net sales: SEK 586 million, up 6% organically excluding trial revenue.
Gross margin in Q3 was 75%, and year-to-date was 74%, both in line with last year.
Adjusted EBIT margin in Q3 was 9%; adjusted EBITDA margin was 19% in Q3 and 18% year-to-date.
Cash position at quarter-end was SEK 280 million, with SEK 120 million available under a credit facility.
Cash flow from investments was negative SEK 61 million, reflecting CapEx and regulatory investments.
Outlook and guidance
Priority is obtaining CE mark for Heart in Europe and preparing the U.S. Heart regulatory file for FDA submission.
Focus on increasing EVLP adoption and expanding service offerings in the U.S., with a strengthened field force.
Liver Assist in Europe will continue to be supported to increase lives saved; U.S. regulatory pathway for Liver is under review for potential acceleration.
Long-term outlook remains strong, with machine perfusion and service models expected to drive significant growth.
Anticipates gradual recovery in global transplant growth through late 2025 and into 2026.
Next XVIVO Perfusion earnings date
Next XVIVO Perfusion earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)